Bruker Corporation (BRKR) AI Stock Analysis

Bruker Corporation develops, manufactures, and distributes scientific instruments, analytical tools, and diagnostic solutions worldwide. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. Its product lineup includes life science tools, mass spectrometry systems, atomic force microscopy, and diagnostic platforms like the MALDI Biotyper for pathogen identification. Bruker also provides electron microscopy, X-ray instrumentation, portable detection systems, and superconducting materials for synchrotron and beamline applications, supporting researchers across biotechnology, multi-omics, drug discovery, and materials science.

Bruker grew revenue from $2.42B in FY2021 to $2.53B in FY2022, $2.96B in FY2023, and $3.37B in FY2024, reaching $3.44B in FY2025. However, annual revenue growth decelerated from 21.7% in FY2021 to 2.1% in FY2025. Gross margin contracted from 50.0% in FY2021 to 45.9% in FY2025, while operating margin declined from 17.1% to 6.9%. Net income decreased from $277.1M in FY2021 to a loss of -$8.6M in FY2025, with net margin at -0.3%. In the latest quarter ended June 30, 2026, quarterly revenue grew 5.2% year-over-year, while quarterly earnings declined 81.8%.

As of June 30, 2026, Bruker held $184.9M in cash and short-term investments against total debt of $1.92B, resulting in net debt of $1.73B. Total assets were $6.05B and shareholders' equity was $2.40B, yielding a debt-to-equity ratio of 0.80 and a current ratio of 1.85. Operating cash flow in FY2025 was $134.1M, down from $251.3M in FY2024, while free cash flow reached $13.9M. In FY2025, the company deployed $120.2M to capital expenditures, $22.8M to dividends, and $10.0M to share buybacks.

Bruker trades at a forward P/E of 13.8x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 2.4x is also lower than the peer median of 4.1x. However, its EV/EBITDA multiple of 39.7x trades well above the peer median of 12.0x, with an enterprise value of $10.69B and a market cap of $8.35B. Over the past year, Bruker returned 44.1%, outpacing the S&P 500 return of 16.8%. Over five years, the stock declined 27.8%, lagging the S&P 500 return of 83.0%.

Bruker pays a quarterly dividend with an annual forward payout of $0.20 per share, resulting in a dividend yield of 0.37%. Its payout ratio stands at 10.9%. The company has paid dividends for 11 consecutive years and delivered a 5-year annualized dividend growth rate of 4.6%. Its last ex-dividend date was September 21, 2026.

Wall Street coverage consists of 5 Strong Buy, 1 Buy, 6 Hold, 0 Sell, and 1 Strong Sell ratings. The mean price target of $63.83 implies a 16.5% upside compared to the last close of $54.80. For the current fiscal year ending December 31, 2026, analysts estimate EPS of $2.12 and revenue of $3.56B. Bruker beat EPS expectations in 3 of the last 4 quarters, and its next earnings date is November 2, 2026.

This page is an AI-written research summary of Bruker Corporation (BRKR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BRKR income statement, BRKR balance sheet, BRKR key metrics, BRKR analyst forecast, BRKR chart. See the BRKR stock overview for the latest quote and news.